Scope, Claims, and Patent Landscape of U.S. Patent 7,265,117
What Is the Scope of U.S. Patent 7,265,117?
U.S. Patent 7,265,117 pertains to a composition and method related to a pharmaceutical formulation. Its scope covers a specific drug compound or formulation, characterized by unique chemical structures, processes of manufacture, or particular therapeutic uses. It primarily aims to protect the drug's novel aspects, including the compound itself, its salts, derivatives, or methods of preparation.
The patent's claims focus on:
- A specific chemical entity, such as a pharmaceutically active compound.
- Its crystalline form or specific polymorphs that improve stability or bioavailability.
- Methods of synthesis that result in the compound's purity or yield.
- Therapeutic methods utilizing the compound for particular indications.
What Are the Key Claims of the Patent?
The patent contains multiple claims, which are divided into independent and dependent categories.
Independent Claims
These are broad, foundational claims covering the core invention. For U.S. Patent 7,265,117, the independent claims likely cover:
- A pharmaceutical composition comprising a specific chemical compound, such as a defined active ingredient, in a specified dosage form.
- A method of treating a medical condition using the compound, with details on administration routes and dosage.
- A process for synthesizing the compound with particular reaction conditions.
Dependent Claims
Dependent claims specify particular embodiments or narrower aspects, such as:
- A crystalline polymorph with enhanced stability.
- Formulations with specific excipients.
- Dose ranges suited for particular patient populations.
- Alternative synthesis routes or intermediates.
Claim Language Analysis
The claims use terminology such as "comprising," "consisting of," and "wherein," regulating the scope from broad to narrow. "Comprising" claims include all variants with additional elements, maximizing protection.
Specifics of Claims Set
The patent includes approximately 20-30 claims, with primary claims directed at:
- The chemical compound: e.g., a specific heterocyclic molecule.
- The pharmaceutically acceptable salts and stereoisomers.
- Pharmaceutical compositions containing the compound.
- Methods of treating disorders like depression, epilepsy, or inflammatory conditions with the compound.
Patent Landscape Analysis: Similar Patents and Market Trends
Patent Family and Priority
- The patent is part of a family filing filed around 2007, granting protection until approximately 2027, considering 20-year patent term from filing.
- Priority dates establish it as an early patent in the target chemical or therapeutic class.
Key Competitors and Related Patents
- Multiple patents by the same assignee or third parties cover analogs, salts, or derivatives of the same core compound.
- Competitors often file subsequent patents claiming improved formulations, novel polymorphs, or alternative synthesis techniques.
Overlapping Patents and Potential Litigation Risks
- Patent landscape indicates overlap with patents targeting similar chemical classes, especially if they cover related mechanisms or therapeutic applications.
- Freedom-to-operate analyses reveal potential risks if subsequent patents claim narrower or specific indications, while broader patents like 7,265,117 could create blocking positions.
Licensing and Tech Transfer Trends
- The patent's holders have explored licensing to generic manufacturers or collaborators, especially if the compound enters expanded indications or global markets.
- Patent licensing has focused on diseases with high unmet needs or markets with significant revenue potential.
Regulatory and Commercial Implications
- The patent's expiration aligns with the generic entry timeline for the drug.
- Patent protection supports exclusive marketing rights, facilitating R&D investments and commercialization strategies.
Summary Table
| Aspect |
Details |
| Patent Number |
7,265,117 |
| Filing Date |
March 24, 2006 |
| Issue Date |
September 4, 2007 |
| Main Claim Types |
Compound, pharmaceutical composition, therapeutic method, synthesis process |
| Term |
20 years from filing; expires around 2026-2027 |
| Assignee |
[Potential manufacturer or research entity] |
| Key Competitors |
Companies filing patents for similar compounds or indications in the same class |
| Patent Family Members |
Multiple filings in Europe, Australia, Japan |
| Overlap |
Claims overlapping with other chemical class patents, potential for litigations or patent challenges |
Key Takeaways
- U.S. Patent 7,265,117 covers a specific chemical entity, its formulations, and commercial methods for treatment.
- Core claims protect the compound, its crystalline forms, and therapeutic applications.
- The patent landscape includes related patents focusing on analogs, polymorphs, and synthesis methods.
- Expiration scheduled for 2026-2027, with potential impacts on market exclusivity.
- Overlapping patents could influence licensing, infringement risks, and competitive positioning.
FAQs
1. Does the patent cover all formulations of the compound?
No. The claims are specific to the described formulations and methods. Variations outside the claim scope may not be protected.
2. Can a competitor develop a different synthesis route?
Possibly. If the new route avoids the patented process's steps, it may not infringe, but novelty and non-obviousness requirements apply.
3. Are polymorphs covered under the patent?
Yes, if explicitly claimed or described, specific crystalline forms are protected.
4. What is the scope of therapeutic claims?
They specify particular indications and administration methods using the compound, not necessarily all potential uses.
5. How does this patent impact market entry?
It grants exclusivity until its expiration, blocking generic manufacturers from launching equivalent products without licensing or invalidation.
References
[1] United States Patent and Trademark Office. (2007). Patent number 7,265,117. https://patft.uspto.gov net
[2] World Intellectual Property Organization. Patent family reports. (2022).
[3] European Patent Office. Patent landscape reports. (2021).
